Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registries.

Autor:	Ørnbjerg LM; Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark lykke.midtboell.oernbjerg@regionh.dk., Georgiadis S; Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark., Kvien TK; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway., Michelsen B; Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.; Research Unit, Sørlandet Hospital, Kristiansand, Norway., Rasmussen S; Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark., Pavelka K; Institute of Rheumatology, Prague, Czech Republic.; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Zavada J; Institute of Rheumatology, Prague, Czech Republic.; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Loft AG; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark., Kenar G; Department of Internal Medicine, Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey., Solmaz D; Izmir Katip Celebi University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir Ataturk Education and Research Hospital, Izmir, Turkey., Glintborg B; Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; The DANBIO registry, Copenhagen, Denmark., Rodrigues A; Rheumatology Unit, Hospital dos Lusíadas, Lisbon, Portugal.; Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal.; EpiDoC unit, CEDOC, Nova Medical School, Lisbon, Portugal., Santos MJ; Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal.; Instituto Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal.; Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal., Di Guiseppe D; Division of Clinical Epidemiology, Department of Medicin Solna, Karolinska Institutet, Stockholm, Sweden., Wallman JK; Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden., Ciurea A; Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Nissen MJ; Department of Rheumatology, University Hospital of Geneva, Geneva, Switzerland., Rotar Z; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia., Pirkmajer KP; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia., Nordström D; Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland., Hokkanen AM; Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland., Gudbjornsson B; Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Palsson O; Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Hetland ML; Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Østergaard M; Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	RMD open [RMD Open] 2024 Nov 02; Vol. 10 (4). Date of Electronic Publication: 2024 Nov 02.
DOI:	10.1136/rmdopen-2024-004644
Abstrakt:	Objectives: To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a large contemporary cohort. Methods: Data from 2939 patients with axial spondyloarthritis (axSpA) starting their first tumour necrosis factor inhibitor in nine European registries were pooled and analysed. Receiver operating characteristic analyses were performed to identify cut-offs against external criteria. Six-month data including patient and physician global assessments, both ≤1 (0-10 integer scale), and Assessment of SpondyloArthritis International Society partial remission were used for separation of inactive disease (ID) from low disease activity (LDA), while patient and physician global ≤3 were applied as external criteria to separate LDA from high disease activity (HDA). Patient and physician global ≥6 were applied to separate HDA from very high disease activity in baseline data. Results: The three ASDAS cut-offs identified to separate the four disease activity states in the overall patient population were <1.3, <2.0 and >3.5. Cut-offs for ID and LDA in women were higher (<1.5 and <2.0, respectively) than in men (<1.3 and <1.9), as were cut-offs in patients ≥45 years (<1.5 and <2.2) versus ≤34 years (<1.2 and <1.9) and 35-44 years (<1.3 and <1.8). Cut-offs were independent of calendar time and disease duration. Conclusions: Re-evaluation of ASDAS cut-offs for disease activity states in a large multi-national axSpA cohort resulted in cut-offs similar to those currently endorsed. Differences in cut-offs between sex and age groups for ID and LDA were observed, but the differences were minor. Competing Interests: Competing interests: LMO: research support paid to employer from Novartis and UCB. SG: research support paid to employer from Novartis and UCB. TKK: fees for speaking: Janssen, Sandoz, Grünenthal, UCB, fees for consulting: AbbVie, Galapagos, Janssen, Pfizer, Sandoz, Data monitoring committee: AbbVie. Received research funding to Diakonhjemmet Hospital from AbbVie, BMS, Novartis, Pfizer and UCB. BM: research support paid to employer from Novartis, Speaker fees from Novartis. SR: research support paid to employer from Novartis. KP: speaker fees from Eli Lilly, AbbVie, Novartis, UCB, Janssen, AstraZeneca. JZ: consultancy and speaker fees from Abbvie, Eli Lilly, Novartis, Pfizer, Sandoz, Sobi, Astra Zeneca, Celltrion. AGL: consultancy or advisor fees from Janssen, Lilly, Novartis, Pfizer, and UCB, and speaking fees or grants from AbbVie, Novartis, Pfizer, and UCB. GK: none. DS: none. BG: research grants from Pfizer, Abbvie, BMS, Sandoz. AR: none. MJS: speaker fees from Abbvie, AstraZeneca, Janssen, Lilly, Medac, Novartis, Pfizer. DDG: none. JKW: speaker fees from AbbVie, Amgen. Research support from AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. AC: none. MJN: consulting fees from AbbVie, Eli Lilly, Janssens, Novartis, Pfizer. ZR: consultancy and speaker fees from Abbvie, Amgen, AstraZeneca, Boehringer, Biogen, Eli Lilly, Janssen, Medis, MSD, Novartis, Pfizer, Sandoz Lek. KPP: consultancy and speaker fees from Abbvie, Boehringer, Eli Lilly, Janssen, Medis, MSD, Novartis, Pfizer, Sandoz Lek, Sobi. DN: consultancy from BMS, Lilly, MSD, Novartis, Pfizer, UCB and research grant from MSD. AMH: travel grants from Janssen-Cilag, Abbvie and UCB. BG: none. OP: none. MLH: speaking fees from Pfizer, Medac, Sandoz (no personal income, institution); speaking fee for Novartis (personal income), research grants from Abbvie, Biogen, BMS, Celltrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Fonden, MSD, Medac, Pfizer, Roche, Samsung Biopies, Sandoz, Novartis, Nordforsk. MO: consultancy fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Galapagos, Gilead, Hospira, Janssen, MEDAC, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, speaker fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Galapagos, Gilead, Hospira, Janssen, MEDAC, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Research grants from AbbVie, Amgen, BMS, Merck, Celgene, Eli Lilly, Novartis and UCB. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu